about
Astrocytes in Oligodendrocyte Lineage Development and White Matter PathologyFetal Alcohol Spectrum Disorders: An Overview from the Glia PerspectiveA New Outlook on Mental Illnesses: Glial Involvement Beyond the GlueMegalencephalic leukoencephalopathy with subcortical cysts protein-1 modulates endosomal pH and protein trafficking in astrocytes: relevance to MLC disease pathogenesisA canine orthologue of the human GFAP c.716G>A (p.Arg239His) variant causes Alexander disease in a Labrador retriever.Brain edema: a valid endpoint for measuring hepatic encephalopathy?Isolated macrocerebellum: description of six cases and literature reviewAstrocytic TDP-43 pathology in Alexander diseaseWhite matter astrocytes in health and disease.Recommendations to enable drug development for inherited neuropathies: Charcot-Marie-Tooth and Giant Axonal Neuropathy.A mutation in the canine gene encoding folliculin-interacting protein 2 (FNIP2) associated with a unique disruption in spinal cord myelination.Astrocyte heterogeneity across the brain and spinal cord occurs developmentally, in adulthood and in response to demyelination.Effects of traumatic brain injury on reactive astrogliosis and seizures in mouse models of Alexander disease.Type 1 equilibrative nucleoside transporter regulates astrocyte-specific glial fibrillary acidic protein expression in the striatum.Glia and neurodevelopment: focus on fetal alcohol spectrum disorders.Astrocyte Dysfunction in Developmental Neurometabolic Diseases.Identification of a novel nonsense mutation in the rod domain of GFAP that is associated with Alexander disease.Neurological and psychiatric disorders as a neuroglial failure.Astrogliosis.Lithium Decreases Glial Fibrillary Acidic Protein in a Mouse Model of Alexander Disease.Alexander Disease: A Novel Mutation in GFAP Leading to Epilepsia Partialis ContinuaAstrogliopathology in neurological, neurodevelopmental and psychiatric disorders.CSF and Blood Levels of GFAP in Alexander DiseaseAtypical MRI features in familial adult onset Alexander disease: case report.Nitric oxide mediates glial-induced neurodegeneration in Alexander diseaseGlucocorticoid treatment of astrocytes results in temporally dynamic transcriptome regulation and astrocyte-enriched mRNA changes in vitro.An In Vivo Pharmacological Screen Identifies Cholinergic Signaling as a Therapeutic Target in Glial-Based Nervous System Disease.A cellular star atlas: using astrocytes from human pluripotent stem cells for disease studiesGFAP expression as an indicator of disease severity in mouse models of Alexander disease.Astroglia in neurological diseasesAdult-onset Alexander disease, associated with a mutation in an alternative GFAP transcript, may be phenotypically modulated by a non-neutral HDAC6 variantPATHOBIOLOGY OF NEURODEGENERATION: THE ROLE FOR ASTROGLIA.Caspase cleavage of GFAP produces an assembly-compromised proteolytic fragment that promotes filament aggregation.Deficits in adult neurogenesis, contextual fear conditioning, and spatial learning in a Gfap mutant mouse model of Alexander diseaseThe role of gigaxonin in the degradation of the glial-specific intermediate filament protein GFAP.Astrocyte barriers to neurotoxic inflammation.Glial progenitor cell-based treatment of the childhood leukodystrophies.Proteome of brain glia: the molecular basis of diverse glial phenotypes.Emerging role of autophagy in pediatric neurodegenerative and neurometabolic diseases.ASTROCYTES: EMERGING STARS IN LEUKODYSTROPHY PATHOGENESIS.
P2860
Q26744749-D8D98FAA-45C8-428B-818A-0E448CF27F9CQ26770451-8C203D1B-7059-474D-9A58-DECA285A9C2CQ26770756-D894B044-20E0-4836-8E26-F9CFB8F2A5FAQ30577254-EE95A7BC-D50D-4E69-ABDC-FBD855DC4C94Q30757333-0B300254-D12D-48B1-9305-FC86FED6C16EQ31106217-A297E0C6-65E3-419C-9C5C-7E971FD2DD7AQ31148159-E04600BE-EE98-497F-9C63-17481C92EB26Q33575134-6D637860-7DE0-48E8-BB21-DF2D18A5E3ACQ33594651-DF8F19EF-8441-40DC-B5F2-BC4CF5DFAE44Q33622527-31E1BB3A-40F8-4D4C-BDB3-CB6DA634B9F4Q33631202-50216C93-42B9-4DD9-A259-836F4485D01DQ33897709-EA46A08A-9B64-4202-A1F0-3A4B9328CF9BQ34183917-EE3EF6BF-03BE-4028-945F-F14741B82AFFQ34259303-E18704AC-6C38-48FF-8DAC-35BFC2CB52F7Q34488287-C35BB63A-CF07-47CE-B729-2D5A757D9968Q34679071-DE912012-BDD5-4428-9593-0638955109B2Q34705157-93CA9873-E7EF-41F8-9F5D-9A9C2B123F31Q34770769-FE393E28-DDA6-40C2-8A9E-6E99590F423CQ35045104-5BDBB2CB-F050-4851-88B0-C810C02B6BEBQ35778386-74FADADA-E19E-4C76-9F4B-461F35B4CFACQ35882314-FEDB535A-DCBD-4394-A3E1-8ED0891E6B2FQ36118835-20FCE538-8E92-4CD3-910E-6C1728CEFE9AQ36154360-25CB3060-2C7C-4453-8261-FC4ACCDCD9C9Q36183264-FDA6A5BE-3887-49B2-B89B-62B1FE9E3AEFQ36360991-410D6488-2F83-4FB6-AA72-7D95590B6950Q36530891-05509B56-DEF3-4DDF-8390-DBC38F27499FQ36534299-450710B0-FCEB-47D9-ACE2-851E47188499Q36682196-F2CEFD47-9732-43B2-B2BA-8BDCF8671D36Q36706156-537AB640-D00A-4E69-B9FB-06CA9928016EQ36819902-3BF64CC6-C00F-479E-90F8-5DAEDA834BFEQ36846924-1FD7FE59-B50C-47A5-AB90-76E88ECB18B6Q36998893-83D0DD41-A732-4CB8-907D-811EEB2197F9Q37323740-6DA24D19-739F-48D3-B073-2BC52001D300Q37325408-4F625831-1A52-44BF-B1DA-FE1B261BA160Q37503447-F5A61EAE-E9CB-4429-BC8A-E2DD49F81B2CQ37597818-5B2AF61E-F6F1-41AE-9545-6538AC80E2A4Q37684345-743B67B0-1B8E-4BFA-B82F-F96B391073C2Q38152439-E71501CB-0FE0-4B45-9767-25894A80E705Q38156022-5F59C3C3-39A2-4E7A-B4F8-321AFD0FE9AEQ38171484-FEF7EC89-FF43-4752-97C9-5B701A7784AE
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Alexander disease
@ast
Alexander disease
@en
Alexander disease
@nl
type
label
Alexander disease
@ast
Alexander disease
@en
Alexander disease
@nl
prefLabel
Alexander disease
@ast
Alexander disease
@en
Alexander disease
@nl
P2093
P2860
P3181
P1476
Alexander disease
@en
P2093
Albee Messing
James E Goldman
Mel B Feany
Michael Brenner
P2860
P304
P3181
P356
10.1523/JNEUROSCI.5384-11.2012
P407
P577
2012-04-11T00:00:00Z